Pursuant to Regulation 30 SEBI (LODR) Regulations, 2015- Change in Management
HIKAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 11.5 pts less than Nifty Microcap 250 and 11.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Hikal Ltd reported a net loss of Rs 487 million for FY2026, a sharp reversal from profit of Rs 909 million in FY2025. Revenue declined 8% to Rs 17,126 million from Rs 18,598 million. The loss was driven by exceptional items totalling Rs 851 million, including a Rs 471 million impairment charge for plant repurposing and Rs 380 million from new labour code implementation. The Board recommended a final dividend of Rs 0.40 per share (20%), bringing total FY26 dividend to Rs 0.60 per share (30%), significantly lower than Rs 1.40 per share (70%) paid in FY25. Mr. Sandip Parikh was appointed as Additional Independent Director for a 5-year term. The filing also notes ongoing concerns including a USFDA warning letter for the Jigani facility impacting Pharma segment sales and an environmental compliance matter pending before the Supreme Court.
The company swung to loss, dividend was sharply cut, and regulatory issues (USFDA warning, Supreme Court environmental case) create additional risk for shareholders. The appointment of a new independent director is a routine governance update with limited immediate stock impact.